The global drug delivery technologies market is estimated to be valued at USD 49.79 Bn in 2025 and is expected to exhibit a compound annual growth rate (CAGR) of 12.9% during the forecast period, reaching USD 116.49 Bn by 2032.
The global drug delivery technologies market is expected to record robust growth during the forecast period. This can be attributed to increasing prevalence of chronic diseases and advancements in drug delivery systems.
Technologies such as oral, pulmonary, and transdermal drug delivery have significantly enhanced the efficiency and convenience of therapeutic administration. Moreover, the increasing focus on targeted drug delivery, supported by innovations in nanotechnology, is expected to boost market growth during the forecast period.
The global prevalence of chronic diseases such as diabetes, cardiovascular disorders, and cancer is increasing rapidly. For example, as per the IDF, about 853 million people will be living with diabetes by 2050. This is expected to drive demand for drug delivery technologies during the forthcoming period.
|
Current Event |
Description and its Impact |
|
AI and Machine Learning Revolution in Healthcare |
|
|
Global Aging Population and Chronic Disease Epidemic |
|
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
As per Coherent Market Insights’ latest drug delivery technologies market analysis, oral segment is expected to account for the highest market share of 35.6% in 2025. This dominance is mostly due to the accessibility and convenience offered by oral drug delivery technologies.
Oral drug delivery provides easy self-administration without the need for healthcare professionals. This reduces treatment costs and improves compliance for patients needing long-term medication.
The non-invasive nature of oral delivery also increases patient acceptance and comfort over alternative routes. Oral drugs can be administered discreetly without needles or apparatus. As a result, the target segment is expected to continue its dominance during the forecast period.
Leading companies are focusing on expanding their oral drug delivery solutions to stay ahead of the competition. For example, in August 2025, BioMed X teamed up with Novo Nordisk to develop novel oral-formulation technologies for therapeutic peptides.
The collaboration seeks to develop innovative technologies that improve oral delivery as well as absorption of peptide-based drugs. These innovations will likely boost growth of the target segment in the coming years.
Based on therapeutic area, oncology segment is expected to dominate the industry, capturing 23.6% of the market share in 2025. This is mostly due to rapid advancements in cancer treatment options.
There is significant research underway to develop improved targeted drug carriers as well as combination therapies for oncology. Novel drug delivery systems help combat challenges in achieving required dosage at tumor sites.
Liposomes, polymeric, and antibody-drug conjugates effectively enhance drug loading and binding for chemotherapeutics. These facilitate localized or controlled release of anti-cancer payloads to improve efficacy and safety profiles.
For example, in October 2025, AstraZeneca and Daiichi Sankyo’s antibody-drug conjugate Datroway showed improved survival in aggressive breast cancer patients. This highlights how targeted drug delivery systems are advancing cancer treatment.
Ambulatory surgical clinics segment is expected to lead the global drug delivery technologies industry with a share of 23.62% in 2025. This leadership is attributed to the efficiency advantages of ambulatory clinics over hospitals,
Ambulatory clinics offer day-case surgeries and infusions without overnight hospitalization. This reduces medical costs for lower acuity procedures and infusions. It provides a convenient option to free up hospital bed capacity for serious cases.
Ambulatory clinics also have flexible schedules suited to working patients. Their streamlined workflows as well as dedicated staff deliver targeted care efficiently.
To learn more about this report, Download Free Sample
North America dominates the drug delivery technologies market, with an estimated share of 39.7% in 2025. This is attributable to strong presence of leading pharmaceutical and biotech companies, rising healthcare expenditure, and supportive government policies.
Some major players like Johnson & Johnson and Pfizer have established their primary research headquarters in the U.S. They are developing novel delivery systems, ensuring the dominance of the region.
For instance, Johnson & Johnson received U.S. FDA approval for INLEXZO in September 2025. It is the first and only intravesical drug-releasing system designed to provide extended local delivery of gemcitabine into the bladder.
Asia Pacific is expected to emerge as a highly lucrative market for manufacturers of drug delivery technologies during the forthcoming period. This can be attributed to the increasing healthcare needs of the large patient population and government initiatives to strengthen regional core capabilities in producing sophisticated medical technologies.
Global firms like GlaxoSmithKline PLC have also expanded into nations like China and India to tap growth opportunities. For example, in July 2025, GlaxoSmithKline (GSK) entered into a significant licensing agreement with China's Jiangsu Hengrui Pharmaceuticals.
Together, the two companies will develop innovative medicines, including advanced drug delivery systems. Such development will further contribute to the expansion of drug delivery technologies industry in the region.
The U.S. drug delivery technologies market is poised to exhibit strong growth during the assessment period. This is mostly due to substantial investments in research and development aimed at enhancing the efficacy and convenience of therapeutic solutions.
These efforts are supported by a robust regulatory framework, with the U.S. FDA actively approving innovative drug delivery systems that cater to diverse healthcare needs. For example, the FDA approval of Datroway in 2023 for treating certain types of breast cancer highlights how innovative drug delivery technologies are reaching patients, improving treatment effectiveness as well as minimizing side effects.
China is becoming a happy hunting ground for drug delivery technology manufacturers. This is mostly due to rising healthcare expenditures, growing aging population, and shift toward a patient-centric healthcare approach.
The government’s Healthy China 2030 initiative aims to improve healthcare access, which is expected to boost the market growth significantly. Similarly, rising demand for personalized medicine will likely trigger drug delivery technologies market growth in China.
To learn more about this report, Download Free Sample
| Report Coverage | Details | ||
|---|---|---|---|
| Base Year: | 2024 | Market Size in 2025: | USD 49.79 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2025 To 2032 |
| Forecast Period 2025 to 2032 CAGR: | 12.9% | 2032 Value Projection: | USD 116.49 Bn |
| Geographies covered: |
|
||
| Segments covered: |
|
||
| Companies covered: |
Johnson & Johnson Pvt. Ltd., Pfizer Inc., Novartis AG, Merck & Co., Inc., GlaxoSmithKline PLC, Sanofi S.A., Bayer AG, Abbott Laboratories, 3M Company, Antares Pharma, Alkermes PLC, Vectura Group PLC, Generex Biotechnology Corporation, F. Hoffmann-La Roche Ltd., and Medtronic PLC |
||
| Growth Drivers: |
|
||
| Restraints & Challenges: |
|
||
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
To learn more about this report, Download Free Sample
The incidence of chronic diseases has been steadily increasing worldwide. Conditions such as cancer, diabetes, and cardiovascular diseases are major contributors to global mortality and morbidity.
According to the World Health Organization (WHO), non-communicable diseases (NCDs) currently cause about 74% of all deaths globally. Projections suggest that chronic conditions may account for up to 86% of annual deaths by 2050.
Factors such as rising obesity, and air pollution, have further challenged health systems. These factors highlight the urgent need for innovative drug delivery solutions.
The growing pipeline of biologics and biosimilars offers lucrative opportunities for drug delivery technologies market players. These medicines are driving demand for novel drug delivery technologies.
Biologics are usually administered through injectable routes but have limited shelf life and stability issues when stored at room temperature in traditional delivery forms like vials. This necessitates the need for advanced drug delivery systems such as pre-filled syringes, patch pumps, and auto-injectors that provide benefits of safe and convenient long-term storage and administration of biologics.
The global drug delivery technologies market outlook remains positive. However, the risk of needlestick injuries associated with traditional injectable drug delivery such as syringes and needles might limit market growth to some extent during the forecast period.
Needlestick injuries pose severe health and safety risks to healthcare professionals by exposing them to blood-borne pathogens like hepatitis B, hepatitis C, and HIV. It has been estimated by the World Health Organization (WHO) in November 2023 that around 2 million needlestick injuries occur among healthcare workers globally each year.
Share
Share
About Author
Komal Dighe is a Management Consultant with over 8 years of experience in market research and consulting. She excels in managing and delivering high-quality insights and solutions in Health-tech Consulting reports. Her expertise encompasses conducting both primary and secondary research, effectively addressing client requirements, and excelling in market estimation and forecast. Her comprehensive approach ensures that clients receive thorough and accurate analyses, enabling them to make informed decisions and capitalize on market opportunities.
Missing comfort of reading report in your local language? Find your preferred language :
Transform your Strategy with Exclusive Trending Reports :
Frequently Asked Questions
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
Schedule a meeting with report Author
